Safety, Pharmacokinetics, Bioavailability, Food Effect, Drug-Drug Interaction Study of APX001 Administered Orally
Status:
Completed
Trial end date:
2017-04-20
Target enrollment:
Participant gender:
Summary
This is a Phase l double-blind, placebo-controlled, randomized study to investigate the
safety, tolerability, pharmacokinetics, bioavailability and food effect of single doses of
APX001 administered intravenously and orally, followed by an evaluation of the safety,
tolerability, pharmacokinetics and drug-drug interaction potential of multiple doses of
APX001 administered orally.